Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial.

ABSTRACT:

Background

Retrospective studies have shown that adjuvant treatment improves survival of patients with stage IIB-III esophageal squamous cell carcinoma, but there is no evidence from prospective trials so far.

Materials and methods

Patients with pathological stage IIB-III esophageal squamous cell carcinoma were randomly assigned to receive surgery alone (SA), postoperative radiotherapy (PORT), or postoperative concurrent chemoradiotherapy (POCRT). PORT patients received 54 Gy in 27 fractions; the POCRT group received 50.4 Gy in 28 fractions, plus concurrent chemotherapy with paclitaxel (135-150 mg/m² ) and cisplatin or nedaplatin (50-75 mg/m² ) every 28 days. The primary endpoint was disease-free survival (DFS), and the secondary endpoint was overall su

SUBMITTER: Ni W 

PROVIDER: S-EPMC8649038 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature